Search

Displaying results 1031 - 1040 of 4246 in total
  1. Drug

    Pegfilgrastim

    go.drugbank.com/drugs/DB00019
    ApprovedInvestigational

    [A187607] First developed by Amgen, pegfilgrastim was initially approved by the FDA in 2002 and marketed as Neulasta. It is typically administered via a subcutaneous injection. … [A187601] The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti-cancer

  2. Drug

    Duloxetine

    go.drugbank.com/drugs/DB00476
    ApprovedInvestigational

    [label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. … [A178741] Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder.

  3. Drug

    Metreleptin

    go.drugbank.com/drugs/DB09046
    ApprovedInvestigational

    [A263126] Complications of lipodystrophy include metabolic abnormalities such as hypertriglyceridemia, insulin resistance, diabetes mellitus, and fatty liver disease. … [L41315] In February 2014, metreleptin was approved by the FDA for the treatment of complications of leptin deficiency, as an adjunct to diet, in patients with congenital generalized or acquired generalized

  4. Drug

    Colesevelam

    go.drugbank.com/drugs/DB00930
    ApprovedInvestigational

    Colesevelam is a bile acid sequestrant. Colesevelam is used with exercise and diet changes (restriction of cholesterol and fat intake) to reduce the amount of cholesterol and certain fatty substances in the blood. It works by binding bil...

  5. Drug

    Dulaglutide

    go.drugbank.com/drugs/DB09045
    ApprovedInvestigational

    Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct

  6. Drug

    Dapagliflozin

    go.drugbank.com/drugs/DB06292
    ApprovedInvestigational

    [A6757] Dapagliflozin has been investigated either as monotherapy or as an adjunct treatment with insulin or other oral hypoglycemic agents.

  7. Drug

    Zavegepant

    go.drugbank.com/drugs/DB15688
    ApprovedInvestigational

    [A258195] Small molecule CGRP antagonists are also known as "gepants", and this category includes other drugs such as [rimegepant] and [ubrogepant]. … [L45505] CGRP is released from sensory nerves and acts as a strong vasodilator, and thanks to these properties, it is involved in pain pathways.

  8. Drug

    Fosnetupitant

    go.drugbank.com/drugs/DB14019
    ApprovedInvestigational

    as major side effects. … Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as

  9. Drug

    Somatostatin

    go.drugbank.com/drugs/DB09099
    ApprovedInvestigationalWithdrawn

    well as treat acromegaly [T28]. … Somatostatin is initially secreted as a 116 amino acid precursor, preprosomatostatin, which undergoes endoproteolytic cleavage to prosomastatin.

  10. Drug

    Losartan

    go.drugbank.com/drugs/DB00678
    ApprovedInvestigational

    [L7423] Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide.